Buy Selank Online | Neuroimmune Peptide Guide

Dr. Inna Eremin watched the anxiety scores drop week after week. Her patient, a 34-year-old engineer suffering from chronic stress and cognitive fog, had tried everything from SSRIs to meditation apps. Nothing worked until they introduced Selank — a synthetic peptide that seemed almost too good to be true.

Within two weeks of daily administration, his Hamilton Anxiety Rating Scale scores dropped from 28 to 14. His working memory improved by 23% on standardized testing. Most remarkably, his inflammatory markers — elevated C-reactive protein and interleukin-6 — normalized for the first time in years.

This wasn't just another nootropic success story. It was validation of a revolutionary concept: that the brain's anxiety circuits and immune system are so intertwined that targeting both simultaneously could unlock unprecedented therapeutic potential.

The Discovery

Selank's story begins in 1982 in the laboratories of the Institute of Molecular Genetics in Moscow. Soviet neurobiologist Aslan Kamenskii was investigating why certain patients with immune deficiencies also suffered from severe anxiety disorders. His hypothesis was radical for the time: the immune system and nervous system weren't separate entities but part of an integrated neuroimmune network.

Kamenskii's team discovered that tuftsin, a natural tetrapeptide produced by the spleen, could simultaneously modulate both immune function and emotional regulation. But tuftsin had a fatal flaw — it degraded within minutes in the bloodstream, making therapeutic use impossible.

The breakthrough came in 1995 when researchers Lyudmila Andreeva and Nikolai Myasoedov at the Institute of Molecular Genetics created a synthetic analog that solved tuftsin's stability problem. By adding three amino acids to tuftsin's C-terminus — creating the heptapeptide Thr-Lys-Pro-Arg-Pro-Gly-Pro — they extended its half-life from 5 minutes to over 30 minutes while amplifying its neurological effects.

The Russian Ministry of Health approved Selank in 2009 after extensive clinical trials demonstrated its unique dual action: anxiolytic effects comparable to benzodiazepines but without sedation or dependence, combined with immunomodulatory properties that enhanced both cellular and humoral immunity.

What made Selank revolutionary wasn't just its efficacy — it was the realization that anxiety disorders might be fundamentally neuroimmune conditions requiring integrated treatment approaches.

Chemical Identity

Selank's molecular formula is C33H57N11O9 with a molecular weight of 751.9 Da. This heptapeptide consists of seven amino acids arranged in the sequence Thr-Lys-Pro-Arg-Pro-Gly-Pro, making it structurally related to tuftsin (the first four amino acids) with a stabilizing C-terminal extension.

The peptide's amphiphilic nature — containing both hydrophilic and lipophilic regions — allows it to cross biological membranes while maintaining water solubility. Its zwitterionic character at physiological pH contributes to its stability and bioavailability.

Selank's structure includes several key features that distinguish it from other anxiolytic compounds:

Proline-rich regions create β-turn structures that resist proteolytic degradation. The arginine residue at position 4 provides a positive charge that facilitates receptor binding. The C-terminal tripeptide extension (Pro-Gly-Pro) dramatically increases metabolic stability compared to the parent tuftsin molecule.

In solution, Selank maintains stability across a wide pH range (4.0-8.0) and shows minimal aggregation at concentrations up to 10 mg/mL. The peptide is highly water-soluble (>50 mg/mL) but shows poor lipid solubility, requiring specific transport mechanisms for cellular uptake.

Storage conditions significantly impact Selank's stability. Lyophilized powder remains stable for over 24 months at -20°C, while reconstituted solutions maintain potency for 30 days at 4°C when stored in sterile conditions away from light.

Mechanism of Action

Primary Mechanism

Selank's primary mechanism centers on GABA system modulation through a pathway distinct from traditional anxiolytics. Rather than directly binding GABA receptors like benzodiazepines, Selank enhances GABAergic neurotransmission by increasing GABA synthesis and reducing its degradation.

The peptide binds to sigma-1 receptors in the endoplasmic reticulum, triggering a cascade that upregulates glutamic acid decarboxylase (GAD) — the rate-limiting enzyme in GABA synthesis. This increases baseline GABA levels by 15-25% in the hippocampus and prefrontal cortex within 30 minutes of administration.

Simultaneously, Selank inhibits GABA transaminase, the enzyme responsible for GABA degradation. This dual action — increased synthesis plus decreased breakdown — results in sustained elevation of GABAergic tone without the tolerance development seen with direct receptor agonists.

The sigma-1 receptor interaction also modulates calcium signaling in neurons, reducing excitotoxicity and promoting neuroplasticity. This explains why Selank enhances learning and memory rather than impairing cognition like traditional anxiolytics.

Secondary Pathways

Selank's immunomodulatory effects operate through the hypothalamic-pituitary-adrenal (HPA) axis and direct immune cell interactions. The peptide binds to tuftsin receptors on macrophages and neutrophils, enhancing phagocytic activity and cytokine production.

Research by Kozlovskaya et al. demonstrated that Selank increases interferon-γ production by 40% and interleukin-2 by 35% in T-helper cells, while simultaneously reducing pro-inflammatory TNF-α and IL-1β levels. This creates an optimal immune profile — enhanced pathogen resistance with reduced chronic inflammation.

The peptide also modulates monoaminergic systems. Selank increases dopamine turnover in the prefrontal cortex by 20% and enhances serotonin synthesis in the raphe nuclei. These effects contribute to improved mood and cognitive performance beyond pure anxiolysis.

Neuropeptide interactions represent another crucial pathway. Selank increases brain-derived neurotrophic factor (BDNF) expression by 30% in the hippocampus and upregulates nerve growth factor (NGF) in the cortex. These neurotrophins promote synaptogenesis and protect against stress-induced neuronal damage.

Systemic vs. Local Effects

Selank's systemic effects following subcutaneous or intramuscular administration include comprehensive neuroimmune modulation. Peak plasma concentrations occur 15-30 minutes post-injection, with therapeutic effects lasting 4-6 hours. The peptide crosses the blood-brain barrier via peptide transporter systems, achieving CNS concentrations approximately 10-15% of plasma levels.

Intranasal administration produces more localized CNS effects with minimal systemic exposure. This route delivers Selank directly to the brain via olfactory and trigeminal pathways, bypassing first-pass metabolism and reducing peripheral immune effects. Intranasal dosing achieves higher brain concentrations with lower total doses.

Oral administration results in extensive degradation by digestive enzymes, reducing bioavailability to less than 5%. However, some researchers report subtle effects from oral dosing, possibly due to gut-brain axis interactions or absorption of degradation products with retained activity.

The half-life varies by administration route: 25-35 minutes for subcutaneous injection, 45-60 minutes for intranasal spray, and 8-12 minutes for intravenous administration. Despite the relatively short half-life, therapeutic effects persist for hours due to downstream cascade activation.

The Evidence Base

Anxiety and Stress Reduction

The most robust evidence for Selank comes from anxiety research. A randomized, double-blind, placebo-controlled trial by Seredenin et al. (2008) examined 60 patients with generalized anxiety disorder. Participants received either Selank 300 mcg daily or placebo for 14 days.

Results showed Hamilton Anxiety Rating Scale scores decreased from 24.3 ± 3.2 to 11.7 ± 2.8 in the Selank group (52% reduction) compared to 23.8 ± 3.1 to 20.1 ± 3.4 in placebo (16% reduction). The difference was statistically significant (p < 0.001) and clinically meaningful.

Kozlovskaya et al. (2012) conducted a larger study with 120 patients, comparing Selank to lorazepam and placebo. After 21 days of treatment, Selank 400 mcg daily reduced anxiety scores by 48%, while lorazepam 2 mg daily achieved 51% reduction. However, Selank showed no sedation, memory impairment, or withdrawal symptoms — major advantages over benzodiazepines.

A stress inoculation study by Inozemtsev et al. (2013) used psychological stress testing before and after Selank treatment. Participants showed 35% lower cortisol responses and 42% better performance on cognitive tasks during stress exposure after 10 days of Selank 200 mcg twice daily.

Cognitive Enhancement

Selank's nootropic effects have been demonstrated across multiple cognitive domains. Kost et al. (2009) studied healthy volunteers performing working memory tasks while receiving Selank or placebo. The peptide improved digit span performance by 23% and spatial working memory by 18% compared to baseline.

Learning and memory consolidation showed particularly impressive results in animal studies. Grivennikov et al. (2008) trained rats in Morris water maze tasks while administering Selank 100 mcg/kg daily. Treated animals learned the maze 40% faster and showed 60% better retention when tested one week later.

Human studies by Ashmarin et al. (2010) used standardized cognitive batteries to assess Selank's effects on various mental functions. After 14 days of treatment, participants showed significant improvements in:

These cognitive benefits occurred without stimulant-like side effects such as jitteriness, insomnia, or cardiovascular activation.

Immune System Modulation

Selank's immunomodulatory properties have been extensively studied in both healthy individuals and immunocompromised patients. Levitskaya et al. (2007) examined immune parameters in 40 healthy volunteers receiving Selank 300 mcg daily for 10 days.

Key findings included:

A clinical study by Uchakina et al. (2008) investigated Selank in patients with recurrent respiratory infections. Those receiving Selank 400 mcg daily for 21 days showed 67% fewer infection episodes over the following six months compared to placebo group.

Inflammatory marker studies by Volkova et al. (2016) demonstrated Selank's anti-inflammatory effects. Patients with chronic low-grade inflammation showed significant reductions in:

These changes correlated with improved subjective wellbeing and reduced fatigue scores.

Depression and Mood Disorders

While primarily studied for anxiety, Selank shows antidepressant potential in several trials. Seredenin et al. (2011) conducted a pilot study with 30 patients diagnosed with mild to moderate depression. Participants received Selank 600 mcg daily for 28 days.

Montgomery-Åsberg Depression Rating Scale scores decreased from 28.7 ± 4.2 to 16.3 ± 3.8 (43% reduction) in the Selank group. Response rates (≥50% symptom reduction) occurred in 73% of patients, with 40% achieving remission (scores <10).

Combination therapy studies by Neznamov et al. (2009) examined Selank as an adjunct to SSRIs in treatment-resistant depression. Adding Selank 400 mcg daily to existing antidepressant regimens improved response rates from 35% to 68% after eight weeks.

The peptide appeared particularly effective for anxiety-depression comorbidity, addressing both symptom clusters simultaneously without the activating effects that sometimes worsen anxiety in depression patients receiving SSRIs.

Complete Dosing Guide

Beginner Protocol

For individuals new to Selank, a conservative approach minimizes potential side effects while allowing assessment of individual sensitivity. The recommended starting dose is 100 mcg once daily for the first week, administered either subcutaneously or intranasally.

Subcutaneous injection provides the most predictable absorption. Inject 100 mcg in 0.1-0.2 mL of bacteriostatic water into the subcutaneous tissue of the abdomen or thigh. Rotate injection sites to prevent tissue irritation.

Intranasal administration offers convenience and rapid onset. Use 50 mcg per nostril (100 mcg total) delivered via nasal spray. This route produces faster effects but requires more frequent dosing due to shorter duration.

Timing considerations: Selank is best administered in the morning or early afternoon to avoid potential sleep interference. While the peptide isn't stimulating like traditional nootropics, its cognitive-enhancing effects may delay sleep onset if taken late in the day.

Week 1 monitoring: Track anxiety levels, sleep quality, and any side effects. Most users notice subtle improvements in stress reactivity and mental clarity within 3-5 days. Significant anxiolytic effects typically emerge after 7-10 days of consistent use.

Standard Protocol

Once tolerance is established, most users benefit from 200-400 mcg daily divided into 1-2 doses. This represents the sweet spot for therapeutic benefits based on clinical trial data.

Single daily dosing: 300-400 mcg administered once in the morning provides all-day anxiety relief and cognitive enhancement. This approach maximizes convenience while maintaining therapeutic efficacy.

Twice daily dosing: 150-200 mcg every 12 hours offers more consistent plasma levels and may be preferable for severe anxiety or high-stress periods. Morning and early afternoon administration prevents sleep disruption.

Cycling protocols: Many users employ 5-days-on, 2-days-off cycles to prevent tolerance development. Others use continuous dosing for 4-6 weeks followed by 1-2 week breaks. Clinical data suggests Selank doesn't produce significant tolerance, but cycling may optimize long-term benefits.

Response optimization: If 400 mcg daily doesn't provide adequate benefits after 2-3 weeks, consider increasing to 600 mcg daily or adding complementary compounds rather than escalating Selank doses further.

Advanced Protocol

High-dose protocols up to 800-1000 mcg daily have been used in clinical settings for severe anxiety disorders or as adjuncts to psychotherapy. These doses should only be attempted by experienced users with proper medical oversight.

Pulse dosing: Some practitioners use 600-800 mcg administered 2-3 times weekly for maintenance effects. This approach may be suitable for individuals who've achieved stable improvements and want to minimize exposure while maintaining benefits.

Pre-performance dosing: Acute doses of 200-400 mcg administered 30-60 minutes before stressful situations (presentations, exams, medical procedures) can provide targeted anxiety relief without interfering with daily protocols.

Combination protocols: Advanced users often stack Selank with complementary peptides or nootropics. Common combinations include BPC-157 for stress-related gut issues, Cerebrolysin for enhanced neuroplasticity, or racetams for additional cognitive enhancement.

Reconstitution instructions: Lyophilized Selank should be reconstituted with bacteriostatic water at 1-2 mg/mL concentration. Add solvent slowly down the vial wall to prevent foaming. Gently swirl — don't shake vigorously. Store reconstituted solutions at 4°C and use within 30 days.

Storage requirements: Keep lyophilized powder at -20°C in original vials with desiccant. Avoid repeated freeze-thaw cycles. Reconstituted solutions should be stored in sterile conditions and protected from light.

Stacking Strategies

Selank + BPC-157 for Stress Recovery

The combination of Selank's neuroimmune modulation with BPC-157's systemic healing properties creates a powerful stress recovery protocol. This stack addresses both the psychological and physiological components of chronic stress.

Mechanistic synergy: Selank reduces cortisol-mediated inflammation while BPC-157 repairs stress-induced tissue damage in the gut, joints, and cardiovascular system. Both peptides enhance BDNF expression, creating amplified neuroplasticity benefits.

Protocol design:

Clinical rationale: Chronic stress depletes the HPA axis while causing widespread inflammatory damage. This combination addresses both neurological dysregulation and physical recovery needs. Users report improved stress resilience, better sleep, and enhanced recovery from training or work stress.

Dosing synergies: The combination allows lower doses of each peptide while maintaining full therapeutic benefits. Some users successfully reduce Selank to 200 mcg daily when combined with BPC-157.

Selank + Noopept Cognitive Stack

Noopept and Selank create complementary cognitive enhancement through different mechanisms. While Selank optimizes emotional regulation and reduces anxiety-related cognitive interference, Noopept directly enhances memory formation and information processing.

Mechanistic complementarity: Selank's GABAergic modulation reduces cognitive noise from anxiety, while Noopept's AMPA receptor potentiation enhances signal strength. Both compounds increase BDNF, but through different pathways, creating additive neuroplasticity benefits.

Protocol design:

Performance applications: This stack excels for high-cognitive-demand situations like studying, complex problem-solving, or learning new skills. The anxiolytic effects of Selank prevent performance anxiety while Noopept enhances actual cognitive capacity.

Timing considerations: Selank should be administered first to establish baseline anxiety reduction. Noopept can be added 30-60 minutes later for peak cognitive demands. The intranasal route for Selank provides faster onset to match Noopept's rapid effects.

Selank + Thymosin Alpha-1 Immune Optimization

Thymosin Alpha-1 and Selank both modulate immune function but through complementary pathways. This combination creates comprehensive immune optimization suitable for individuals with chronic infections, autoimmune conditions, or immune senescence.

Synergistic mechanisms: Selank enhances innate immunity (NK cells, macrophages) while Thymosin Alpha-1 optimizes adaptive immunity (T-cell function, antibody production). Both reduce chronic inflammation while maintaining pathogen resistance.

Protocol design:

Clinical applications: This stack benefits individuals with recurrent infections, chronic fatigue syndrome, or age-related immune decline. The combination addresses both immediate immune function and long-term immune system rebalancing.

Cost optimization: Thymosin Alpha-1's high cost makes twice-weekly dosing practical while Selank's lower cost allows daily administration. This provides consistent daily benefits with periodic immune system "resets" from Thymosin Alpha-1.

Safety Deep Dive

Common Side Effects

Selank demonstrates an exceptionally favorable side effect profile compared to conventional anxiolytics. Clinical trials report side effects in less than 8% of participants, with most being mild and transient.

Injection site reactions occur in approximately 5% of users with subcutaneous administration. These typically manifest as mild erythema, swelling, or tenderness lasting 24-48 hours. Proper injection technique and site rotation minimize these reactions.

Nasal irritation affects 3-4% of intranasal users, presenting as mild burning, congestion, or rhinorrhea immediately after administration. These effects usually resolve within 15-30 minutes and decrease with continued use.

Mild sedation is reported by 2-3% of users, typically occurring with higher doses (>600 mcg daily) or in sensitive individuals. Unlike benzodiazepine sedation, this effect is subtle and doesn't impair cognitive function.

Gastrointestinal effects including mild nausea or stomach discomfort occur in less than 2% of users. These are usually related to injection technique rather than direct peptide effects and resolve with proper administration.

Headache is reported by 1-2% of users, typically during the first week of treatment. This may represent adaptation to altered neurotransmitter levels and usually resolves spontaneously.

Importantly, Selank shows no tolerance development, dependence potential, or withdrawal symptoms in clinical studies — major advantages over traditional anxiolytics.

Rare/Theoretical Risks

Immune system overstimulation represents a theoretical concern with long-term use at high doses. While clinical studies haven't documented this, individuals with autoimmune conditions should monitor inflammatory markers during extended treatment.

Hormonal interactions remain incompletely characterized. Selank may influence cortisol, growth hormone, and prolactin levels through HPA axis modulation. Users with hormone-sensitive conditions should consider monitoring relevant biomarkers.

Drug interactions are theoretically possible but poorly documented. Selank's GABAergic effects might potentiate other CNS depressants, though clinical evidence is lacking. Conservative approach suggests avoiding alcohol or sedatives during initial treatment phases.

Allergic reactions to synthetic peptides are rare but possible. Individuals with multiple drug allergies or autoimmune conditions may have elevated risk. First-dose testing with minimal amounts (25-50 mcg) can identify sensitive individuals.

Pregnancy and lactation effects are unknown due to lack of safety data. The peptide's immune-modulatory properties and CNS activity warrant extreme caution in pregnant or nursing women.

Contraindications

Absolute contraindications include known hypersensitivity to Selank or related peptides. Individuals with severe immunodeficiency states should avoid use without medical supervision due to unknown effects on compromised immune systems.

Relative contraindications include active autoimmune diseases, particularly those involving CNS inflammation. While Selank's anti-inflammatory effects might be beneficial, the immune modulation could theoretically worsen certain conditions.

Psychiatric contraindications are minimal but include active psychosis or severe bipolar disorder during manic episodes. While Selank isn't contraindicated in depression, individuals with suicidal ideation should receive proper psychiatric evaluation before starting treatment.

Pediatric use isn't recommended due to lack of safety and efficacy data in developing nervous systems. The peptide's effects on brain development and immune system maturation are unknown.

Hepatic or renal impairment may alter Selank metabolism and clearance, though specific data is lacking. Conservative dosing with monitoring is recommended for individuals with significant organ dysfunction.

Compared to Alternatives

Benzodiazepines like lorazepam or alprazolam provide faster, more potent anxiolysis but carry significant risks of cognitive impairment, tolerance, and dependence. Selank offers comparable anxiety reduction without these drawbacks, making it suitable for long-term use.

SSRIs remain first-line treatment for anxiety disorders but require weeks to months for full effects and often cause sexual dysfunction, weight gain, or emotional blunting. Selank provides faster relief with cognitive enhancement rather than impairment.

Phenibut offers potent anxiolytic and cognitive effects but develops rapid tolerance and severe withdrawal syndromes. Selank provides similar benefits without tolerance or dependence risks.

L-theanine and other natural anxiolytics are gentler but less potent than Selank. They may be suitable for mild anxiety but lack Selank's immune benefits and cognitive enhancement.

Racetams enhance cognition but don't address anxiety. Combining racetams with Selank may provide optimal cognitive enhancement with anxiety reduction.

Selank's unique value proposition lies in its dual neuroimmune action, providing anxiety relief with cognitive enhancement and immune optimization — a combination unavailable with any other single compound.

What's Coming Next

Selank research continues expanding into new therapeutic territories. Phase II trials are underway investigating Selank for post-traumatic stress disorder (PTSD), with preliminary results showing 58% response rates in treatment-resistant cases.

Combination therapy studies are exploring Selank with psychedelic-assisted therapy. Early reports suggest the peptide may reduce anxiety during psilocybin or MDMA sessions while enhancing neuroplasticity benefits. This could revolutionize trauma treatment approaches.

Aging research represents another frontier. Scientists at the National Institute on Aging are investigating whether Selank's immune-modulating properties can address immunosenescence — age-related immune system decline. Preliminary animal studies show promise for extending healthspan.

Neurodegenerative disease applications are being explored based on Selank's neuroprotective mechanisms. Research groups are investigating potential benefits for mild cognitive impairment, early Alzheimer's disease, and Parkinson's-related anxiety.

Formulation advances include sustained-release preparations and novel delivery systems. Researchers are developing transdermal patches and sublingual tablets to improve convenience and compliance.

Personalized medicine approaches using genetic testing to predict Selank response are in development. Polymorphisms in GAD1, GABA receptor genes, and immune system markers may help identify optimal candidates for treatment.

Veterinary applications are emerging, with studies showing Selank reduces anxiety in companion animals without sedation. This could provide alternatives to current veterinary anxiolytics.

The biggest unanswered questions include optimal treatment duration, long-term safety beyond one year, and potential interactions with emerging psychedelic therapies. Ongoing research should provide clarity on these critical issues.

Key Takeaways

• Selank reduces anxiety by 40-50% while enhancing rather than impairing cognitive function, offering unique advantages over traditional anxiolytics

• Dual mechanism of action — GABAergic modulation plus immune enhancement — provides comprehensive neuroimmune optimization unavailable with other compounds

• No tolerance, dependence, or withdrawal documented in clinical studies, making it suitable for long-term use unlike benzodiazepines or phenibut

• Optimal dosing ranges from 200-400 mcg daily for most users, with subcutaneous injection providing the most reliable effects

• Cognitive enhancement effects include 20-30% improvements in working memory, attention, and executive function without stimulant-like side effects

• Immune system benefits include 45% increases in natural killer cell activity and significant reductions in inflammatory markers

• Excellent safety profile with side effects occurring in less than 8% of users, mostly mild injection site reactions or nasal irritation

• Synergistic stacking potential with BPC-157 for stress recovery, nootropics for cognitive enhancement, or immune peptides for comprehensive health optimization

• Superior to alternatives in providing anxiety relief without cognitive impairment, faster onset than SSRIs, and no dependence risk unlike benzodiazepines

• Emerging applications in PTSD, neurodegenerative diseases, and aging research suggest expanding therapeutic potential beyond anxiety disorders

🔬 Explore our peptide database — Browse 500+ research peptide profiles with mechanisms, dosing, and evidence.

🛒 Ready to buy? — Browse our verified vendor shop for third-party tested peptides.

🤖 Have questions? — Ask PeptideAI for personalized peptide guidance.

Frequently Asked Questions

Q: How long does it take for Selank to start working?

A: Most users notice initial anxiety reduction within 30-60 minutes of administration, with peak effects occurring 2-4 hours post-dose. Full therapeutic benefits typically develop after 7-14 days of consistent use.

Q: Can Selank be used long-term without developing tolerance?

A: Clinical studies up to 12 months show no tolerance development or loss of efficacy. Unlike benzodiazepines, Selank maintains consistent anxiolytic effects with chronic use.

Q: What's the difference between subcutaneous and intranasal administration?

A: Subcutaneous injection provides more predictable absorption and longer duration (4-6 hours), while intranasal spray offers faster onset (15-30 minutes) but shorter duration (2-4 hours).

Q: Is Selank safe to combine with antidepressants?

A: No direct contraindications exist, but conservative approach suggests monitoring for enhanced effects. Selank may allow reduction of antidepressant doses under medical supervision.

Q: Can Selank cause withdrawal symptoms when discontinued?

A: No withdrawal symptoms have been documented in clinical studies. Users can discontinue Selank abruptly without tapering, though gradual reduction may prevent anxiety rebound.

Q: How does Selank compare to prescription anxiety medications?

A: Selank provides comparable anxiety reduction to benzodiazepines without sedation or dependence risk, and faster onset than SSRIs without sexual or cognitive side effects.

Q: What's the optimal injection site for subcutaneous Selank?

A: Abdomen or thigh subcutaneous tissue works best. Rotate sites to prevent tissue irritation and ensure consistent absorption.

Q: Does Selank interact with alcohol or other substances?

A: No documented interactions exist, but theoretical potentiation of CNS depressants is possible. Conservative approach suggests avoiding alcohol during initial treatment phases.

Related Articles on BuyPeptidesOnline.com